CCM
ICPT

Cadian Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Cadian Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-25,000
Closed -$3.9M – 109
2014
Q4 		$3.9M Hold
25,000
– – 0.1% 90
2014
Q3 		$5.92M Buy
+25,000
New +$6.37M 0.16% 67

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cadian Capital Management's ICPT Position: Q1 2015 in Review

Cadian Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2015, closing a stake of 25,000 shares — an estimated $3.9M sold.

Cadian Capital Management first reported a position in ICPT in Q3 2014 and held it in 2 quarters. The position peaked at $5.92M in Q3 2014. 200 funds tracked by Wall St. Rank hold ICPT as of Q1 2015.

  • Cadian Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Cadian Capital Management sold 25,000 Intercept Pharmaceuticals, Inc. shares in Q1 2015, an estimated $3.9M.
  • Cadian Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 2 quarters.
  • Cadian Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $5.92M in Q3 2014.
  • 200 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2015.

Based on Cadian Capital Management's 13F filing for Q1 2015, filed 14 May 2015.